SCHEMBL4222097

SCHEMBL4222097

CC(=O)Nc1cc(Oc2ccccc2)ccc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.57
CYP2C19 P33261 1/20 0.57
AKR1C3 P42330 3/20 0.51
AKR1C2 P52895 3/20 0.51
MTNR1A P48039 1/20 0.51
MTNR1B P49286 1/20 0.51
POLB P06746 1/20 0.50
MAPK1 P28482 1/20 0.50
GFER P55789 1/20 0.50
CYP1A2 P05177 1/20 0.48
NR1H4 Q96RI1 1/20 0.48
SERPINE1 P05121 1/20 0.48
EPHX1 P07099 1/20 0.48
HPSE Q9Y251 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HPGD P15428 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9158501 0.86 MTNR1A (0.55) CYP2C9AKR1C3MTNR1AMTNR1BCYP1A2
SCHEMBL2271588 0.84 SERPINE1 (0.64) POLBNR1H4SERPINE1HPSEMEN1
SCHEMBL4216870 0.83 HPGD (0.54) CYP2C9CYP2C19MTNR1AMTNR1BNR1H4
SCHEMBL6361641 0.83 AKR1C3 (0.65) AKR1C3AKR1C2MEN1KMT2A
SCHEMBL13890889 0.82 MTNR1A (0.49) CYP2C9CYP2C19MTNR1AMTNR1BCYP1A2
SCHEMBL2269563 0.82 STK39 (0.57) CYP2C9CYP2C19MAPK1GFERCYP1A2
SCHEMBL2268019 0.82 MAPK1 (0.57) CYP2C9CYP2C19POLBMAPK1GFER
SCHEMBL11644513 0.82 HDAC2 (0.61) MTNR1AMTNR1BEPHX1HPGDSMN1; SMN2
SCHEMBL2272774 0.82 KMT2A (0.63) POLBNR1H4SERPINE1HPSEMEN1
SCHEMBL2273436 0.82 PYGM (0.70) NR1H4SERPINE1HPSEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
US-8327467-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2012-12-11 US disclosed
EP-1860098-B1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2012-11-14 EP disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-04-23 US disclosed
EP-1860098-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105474-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP11, MMP3 CYP2C9 2427/4885CYP2C19 2009/4885AKR1C3 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.